Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exiqon and MultiD Sign Development and Distribution Agreement for microRNA qPCR Analysis Solution

Published: Wednesday, May 26, 2010
Last Updated: Wednesday, May 26, 2010
Bookmark and Share
Agreement incorporates a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform.

Exiqon A/S and MultiD Analyzes AB have announced a Development and Distribution Agreement incorporating a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform. The agreement allows Exiqon to sell a fully compatible and comprehensive data analysis solution to complete their microRNA qPCR offering.

“The partnership between MultiD and Exiqon has lead to the development of a customized version of the advanced GenEx data analysis program which has been specifically adapted to allow easy pre-processing and analysis of data from the Exiqon microRNA PCR panels and assays,” said Henrik M. Pfundheller, VP Sales & Marketing of Exiqon.

Pfundheller continued, “Exiqon offers the best performing qPCR reagents for microRNA expression profiling on the market. However, we feel it is just as important that our customers process, normalize and analyze their qPCR data properly and with confidence. The addition of the Exiqon GenEx software to our microRNA qPCR portfolio enables customers to get the most out of their microRNA expression profiling experiments in an easy and convenient way”.

MultiD's GenEx software is well established software for processing and analysis of qPCR data. It includes everything from selection and validation of reference genes, data pre-processing and advanced statistical methods to analyze real-time qPCR data with simple clicks of the mouse. Possibly the most important part of qPCR experiments is the pre-processing of raw data for subsequent statistical analysis. Pre-processing steps need to be performed with consistence, in the correct order and with confidence.

Exiqon's miRCURY LNA™ Universal RT microRNA PCR system offers the best available combination of performance and ease-of-use on the microRNA real-time PCR market. The use of two LNA™-enhanced PCR primers results in both sensitivity and specificity, enabling quantification of very low microRNA levels and discrimination between closely related microRNA sequences.

The universal RT step reduces sample input requirements and technical variation, and saves time in the laboratory. The product line includes microRNA Ready-to-Use PCR panels for sensitive expression profiling of 730 human microRNAs, individual microRNA assays, reference gens and reagent kits.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exiqon Secures Funding to Accelerate Growth
Exiqon A/S has announced the issue of a senior secured note in the amount of DKK 40 million (‘Note’).
Thursday, November 12, 2015
Exiqon Licenses Biomarkers From Aarhus University Hospital
Exiqon A/S has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus University Hospital, Department of Molecular Medicine (MOMA).
Wednesday, December 03, 2014
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Friday, September 12, 2014
Exiqon Licenses Locked Nucleic Acids for Infectious Disease Diagnostics to BD
BD will use Exiqon's proprietary LNA™ technology in defined products for infectious disease diagnostics.
Wednesday, June 23, 2010
Exiqon Appoints President and General Manager of new US Operations
Michael Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area.
Friday, January 06, 2006
Exiqon Wins Ernst & Young Entrepeneur of the Year Award
Exiqon selected as winner in the BIOTECH 2005 category.
Tuesday, November 22, 2005
Exiqon A/S appoints permanent CEO

Monday, February 24, 2003
Scientific News
Assessing the Effectiveness of Genome-Editing Technologies
Researchers have developed a cost-effective and rapid method for assessing edits generated by CRISPR-Cas9 and other genome-editing technologies.
New Cancer Drug Target Found in Dual-Function Protein
Findings from a study from TSRI have shown that targeting a protein called GlyRS might help to halt cancer growth.
Alzheimer's Genetics Point To New Research Direction
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Fix for 3-Billion-Year-Old Genetic Error
Researchers at The University of Texas at Austin have developed a fix that allows RNA to accurately proofread for the first time.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
The Epigenetic Influences of Chronic Pain
Researchers at Drexel University College of Medicine are aiming to identify new molecular mechanisms involved in pain.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!